Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma

Abstract Glioblastoma (GBM) is a highly aggressive, infiltrative malignancy that cannot be completely cured by current treatment modalities, and therefore requires more precise molecular subtype signatures to predict treatment response for personalized precision therapy. Expression subtypes of GBM s...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Dongdong Luo, Aiping Luo, Su Hu, Ganwei Ye, Dan Li, Hailin Zhao, Biao Peng
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2024-07-01
Edice:	Scientific Reports
Témata:	Glioblastoma Molecular subtype Biomarkers Precision medicine Immunotherapy Drug therapy
On-line přístup:	https://doi.org/10.1038/s41598-024-68648-5
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!